IBD & Intestinal Disorders
Conference Coverage
Noteworthy advances in treatment and management of IBD
A team of leading GI clinicians describes the most noteworthy achievements in IBD research over the last year.
Latest News
Defining difficult-to-treat inflammatory bowel disease
A group of experts held a consensus meeting to propose a common operative definition for “difficult-to-treat IBD.”
From the AGA Journals
Nearly 1 in 100 people diagnosed with IBD in the U.S.
The prevalence of IBD in the United States has been gradually increasing over the last decade.
Feature
Humira biosimilars: Five things to know
The launch of eight adalimumab biosimilars so far in 2023 ended Humira’s 20-year monopoly, but it’s not clear yet if these discounted drugs will...
Conference Coverage
Celiac disease: Update on diagnosis and monitoring
The best initial serology test for diagnosis in suspected celiac disease is the tissue transglutaminase IgA antibody.
From the AGA Journals
Biologics, thiopurines, or methotrexate doesn’t affect fertility or birth outcomes in men with IBD
This is the first meta-analysis to assess semen parameters and the risk of adverse outcomes in pregnancy for male patients with IBD who have taken...
From the Journals
Mirikizumab performs well in UC, new data show
Since 2014, the market size of interleukin inhibitors has grown fivefold with the greatest share belonging to IL-23 inhibitors.
Perspectives
Surveillance colonoscopy: When and how to stop
There is an ongoing debate about whether older adults should undergo CRC screening.
Latest News
No link between PPIs and dementia in new study
PPI use was not linked to changes in overall cognitive test scores over time.
From the AGA Journals
IBD study characterizes biologic adherence, confirms nonadherence risk factors
“Identifying patients at risk for nonadherence is important to develop strategies to improve adherence.”